NYLIA 1/35 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Nylia 1/35, and when can generic versions of Nylia 1/35 launch?
Nylia 1/35 is a drug marketed by Aurobindo Pharma and is included in one NDA.
The generic ingredient in NYLIA 1/35 is ethinyl estradiol; norethindrone. There are twenty-six drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the ethinyl estradiol; norethindrone profile page.
Summary for NYLIA 1/35
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 7 |
Patent Applications: | 166 |
Formulation / Manufacturing: | see details |
DailyMed Link: | NYLIA 1/35 at DailyMed |
Anatomical Therapeutic Chemical (ATC) Classes for NYLIA 1/35
US Patents and Regulatory Information for NYLIA 1/35
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aurobindo Pharma | NYLIA 1/35 | ethinyl estradiol; norethindrone | TABLET;ORAL-28 | 207056-001 | Oct 21, 2016 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |